Corbus Pharmaceuticals Holdings, Inc.
0SZI.L
Market Cap$114.83M
Close$
$1.28
86.9% downside
Current Fair Value
86.9% downsideOvervalued by 86.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $114.83 Million |
|---|---|
| Enterprise Value | $97.24 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.42 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corbus Pharmaceuticals Holdings, Inc.
28 employees
CEO: Dr. Yuval Cohen Ph.D. Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid...